Advertisement

PentaVision

Retinal Physician

Article | 2025 American Academy of Ophthalmology Annual Meeting

ELARA 24-Week Data Show Improvements in Wet AMD and DME

Data presented for the first time at AAO 2025 highlight vision gains and reduced retinal thickness in previously treated eyes using flexible aflibercept 8 mg dosing.

By: Diana V. Do, MD
Retinal Physician October 20, 2025

 

During retina subspecialty day, Diana V. Do, MD, presented ELARA trial data showing that treat-and-extend dosing with aflibercept 8 mg achieved meaningful visual and anatomic improvements in patients with prior anti-VEGF therapy.

 

The following transcript has been edited for clarity:

 

Hi, welcome to the Retinal Physician video channel. I'm Diana V. Do, MD. Today at the retina subspecialty day at the American Academy of Ophthalmology, I had the pleasure of presenting the first-time data from the ELARA study.

ELARA is a phase 3b ongoing study looking at flexible dosing of aflibercept 8 mg (Eylea HD; Regeneron) in eyes that received prior treatment for their wet age-related macular degeneration or their diabetic macular edema. These patients received monthly aflibercept 8 mg for the first 7 months and then were switched over to a treat-and-extend protocol. I presented the 24-week data on the first 417 eyes.

What did we find? We saw that in these patients, they were able to have a gain of vision of up to 3 letters in the wet AMD cohort and also about 3 letters in the diabetic macular edema cohort. In addition, they had a reduction in OCT approximately 32 µm in AMD and up to 50 µm in DME. This is a challenging group, because they all had received prior anti-VEGF agents but still had disease activity. The ELARA study provides promising data on flexible dosing of aflibercept 8 mg. Future long-term data will be available soon. Thanks again. RP